BioMarin Pharmaceutical

Results: 48



#Item
1July 13, 2016  Post-Grant for Practitioners Midyear Review of Decisions and Developments at the PTAB

July 13, 2016 Post-Grant for Practitioners Midyear Review of Decisions and Developments at the PTAB

Add to Reading List

Source URL: fishpostgrant.com

Language: English - Date: 2016-07-14 09:55:09
2United States Court of Appeals for the Federal Circuit ______________________ GENZYME THERAPEUTIC PRODUCTS LIMITED PARTNERSHIP,

United States Court of Appeals for the Federal Circuit ______________________ GENZYME THERAPEUTIC PRODUCTS LIMITED PARTNERSHIP,

Add to Reading List

Source URL: www.patentchallenges.com

Language: English - Date: 2016-08-09 02:08:12
3Muscular dystrophy / Biotechnology / Duchenne muscular dystrophy / Sarepta Therapeutics / PTC Therapeutics / Exon skipping / Clinical trial / BioMarin Pharmaceutical / Draft:BMN 044 / Draft:SRP-4044

ROUNDTABLE SURVEY RESULTS Our pilot program in 2015 was very successful. We distributed and collected surveys from all 6 of our Roundtable events, which were held in Boston, MA, Pittsburgh, PA. Los Angeles, CA and Dubl

Add to Reading List

Source URL: jettfoundation.org

Language: English - Date: 2016-01-26 12:45:27
4Contacts: Investors Traci McCarty BioMarin Pharmaceutical Inc

Contacts: Investors Traci McCarty BioMarin Pharmaceutical Inc

Add to Reading List

Source URL: files.shareholder.com

Language: English
    5Privacy Policy and Notice of Information Practices Effective Date: April 27, 2015 BioMarin Pharmaceutical Inc. (

    Privacy Policy and Notice of Information Practices Effective Date: April 27, 2015 BioMarin Pharmaceutical Inc. ("BioMarin") respects the privacy of visitors to its websites and online services and values the confidence o

    Add to Reading List

    Source URL: www.prosensa.eu

    Language: English - Date: 2015-04-27 19:57:39
    6May 27, 2014  BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to Im

    May 27, 2014 BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to Im

    Add to Reading List

    Source URL: www.apjohnventures.com

    Language: English - Date: 2014-05-29 15:30:33
    7Microsoft Word - Apjohn Ventures Fund 2Q10 Letter Final

    Microsoft Word - Apjohn Ventures Fund 2Q10 Letter Final

    Add to Reading List

    Source URL: www.apjohnventures.com

    Language: English
    8TERMS OF USE Effective Date: April 27, 2015 These Terms of Use (“Terms”) govern your access to and use of the websites and online services that we operate and that link to these Terms (the “Services”). Please rev

    TERMS OF USE Effective Date: April 27, 2015 These Terms of Use (“Terms”) govern your access to and use of the websites and online services that we operate and that link to these Terms (the “Services”). Please rev

    Add to Reading List

    Source URL: www.bmrn.com

    Language: English - Date: 2015-04-27 19:57:43
    9Privacy Policy and Notice of Information Practices Effective Date: April 27, 2015 BioMarin Pharmaceutical Inc. (

    Privacy Policy and Notice of Information Practices Effective Date: April 27, 2015 BioMarin Pharmaceutical Inc. ("BioMarin") respects the privacy of visitors to its websites and online services and values the confidence o

    Add to Reading List

    Source URL: www.bmrn.com

    Language: English - Date: 2015-04-27 19:57:39
    10Microsoft Word - SanRafael_MD_42034_HWOL_0415.doc

    Microsoft Word - SanRafael_MD_42034_HWOL_0415.doc

    Add to Reading List

    Source URL: www.calmis.ca.gov

    Language: English - Date: 2015-05-22 11:54:12